Summit Medical LLC

2019-NCOV CORONAVIRUS, SARS-COV-2/2019-NCOV (COVID-19), ANY TECHNIQUE, MULTIPLE TYPES OR SUBTYPES (INCLUDES ALL TARGETS), NON-CDC

3D RENDERING WITH INTERPRETATION AND REPORTING OF COMPUTED TOMOGRAPHY, MAGNETIC RESONANCE IMAGING, ULTRASOUND, OR OTHER TOMOGRAPHIC MODALITY WITH IMAGE POSTPROCESSING UNDER CONCURRENT SUPERVISION; NOT REQUIRING IMAGE POSTPROCESSING ON AN INDEPENDENT WORKSTATION

3D RENDERING WITH INTERPRETATION AND REPORTING OF COMPUTED TOMOGRAPHY, MAGNETIC RESONANCE IMAGING, ULTRASOUND, OR OTHER TOMOGRAPHIC MODALITY WITH IMAGE POSTPROCESSING UNDER CONCURRENT SUPERVISION; REQUIRING IMAGE POSTPROCESSING ON AN INDEPENDENT WORKSTATION

5% DEXTROSE IN LACTATED RINGERS INFUSION, UP TO 1000 CC

ABATACEPT INJECTION

ABOBOTULINUMTOXINA

ACETYLCHOLINE RECEPTOR (ACHR); BINDING ANTIBODY

ACETYLCHOLINE RECEPTOR (ACHR); BLOCKING ANTIBODY

ACETYLCHOLINE RECEPTOR (ACHR); MODULATING ANTIBODY

ACTH STIMULATION PANEL; FOR ADRENAL INSUFFICIENCY THIS PANEL MUST INCLUDE THE FOLLOWING: CORTISOL (82533 X 2)

ACUTE HEPATITIS PANEL THIS PANEL MUST INCLUDE THE FOLLOWING: HEPATITIS A ANTIBODY (HAAB), IGM ANTIBODY (86709) HEPATITIS B CORE ANTIBODY (HBCAB), IGM ANTIBODY (86705) HEPATITIS B SURFACE ANTIGEN (HBSAG) (87340) HEPATITIS C ANTIBODY (86803)

ADALIMUMAB CONC & ABS (LCP 503890)

ADAPTOR/EXTENSION, PACING LEAD OR NEUROSTIMULATOR LEAD (IMPLANTABLE)

ADJACENT TISSUE TRANSFER OR REARRANGEMENT, EYELIDS, NOSE, EARS AND/OR LIPS; DEFECT 10 SQ CM OR LESS

ADMINISTRATION OF INFLUENZA VIRUS VACCINE

ADRENOCORTICOTROPIC HORMONE (ACTH) LEVEL

AEROSOL INHALATION OF PENTAMIDINE FOR PNEUMOCYSTIS CARINII PNEUMONIA TREATMENT OR PROPHYLAXIS

AFAMELANOTIDE IMPLANT, 1 MG

AFP TETRA (LCP 017319)(ESTRIOL)

AFP TETRA (LCP 017319)(INHIBIN A)

AGALSIDASE BETA INJECTION

AGGLUTININS, FEBRILE (EG, BRUCELLA, FRANCISELLA, MURINE TYPHUS, Q FEVER, ROCKY MOUNTAIN SPOTTED FEVER, SCRUB TYPHUS), EACH ANTIGEN

ALBUMIN (HUMAN), 25%, 20 ML

ALBUMIN (HUMAN), 5%, 250 ML

ALBUMIN ISCHEMIA MODIFIED

ALBUMIN; URINE (EG, MICROALBUMIN), SEMIQUANTITATIVE (EG, REAGENT STRIP ASSAY)

ALBUTEROL, UP TO 2.5 MG AND IPRATROPIUM BROMIDE, UP TO 0.5 MG, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME

ALDESLEUKIN INJECTION

ALLERGEN SPECIFIC IGE; QUALITATIVE, MULTIALLERGEN SCREEN (EG, DISK, SPONGE, CARD)

ALLERGEN SPECIFIC IGE; QUANTITATIVE OR SEMIQUANTITATIVE, CRUDE ALLERGEN EXTRACT, EACH

ALLERGEN SPECIFIC IGE; QUANTITATIVE OR SEMIQUANTITATIVE, RECOMBINANT OR PURIFIED COMPONENT, EACH

ALLOCELL AF BONE FIBERS 5CC

ALLOWRAP DS OR DRY, PER SQUARE CENTIMETER

ALPHA 1 PROTEINASE INHIBITOR

ALPHA-1-ANTITRYPSIN (PROTEIN) BLOOD TEST, PHENOTYPE

ALPHA-FETOPROTEIN (AFP); AFP-L3 FRACTION ISOFORM AND TOTAL AFP (INCLUDING RATIO)

ALPHA-FETOPROTEIN (AFP); AMNIOTIC FLUID

ALTEPLASE 2 MG INTRA-CATHETER SOLUTION [19101]

ALTEPLASE RECOMBINANT

ALTUVIIIO PER FACTOR VIII IU

AMINO ACIDS, 2 TO 5 AMINO ACIDS, QUANTITATIVE, EACH SPECIMEN

AMINO ACIDS, 6 OR MORE AMINO ACIDS, QUANTITATIVE, EACH SPECIMEN

AMINOLEVULINIC ACID HCL TOP

AMINOLEVULINIC ACID, 10% GEL

AMNIOTIC FLUID SCAN

AMPHOTERICIN B LIPID COMPLEX

AMPHOTERICIN B LIPOSOME INJ

AMPICILLIN 500 MG SOLUTION FOR INJECTION [13513]

AMPICILLIN-SULBACTAM 1.5 GRAM SOLUTION FOR INJECTION [14372]

ANACAULASE-BCDB 8.8% GEL 1 G